ライフサイエンスコーパス: placebo effect

1 s opiate and dopamine, are involved with the placebo effect.

2 Some patients may respond, if only via a placebo effect.

3 d such study designs are very susceptible to placebo effect.

4 trated to be effective only by virtue of the placebo effect.

5 been whether a given therapy has more than a placebo effect.

6 ble reports were demonstrating an element of placebo effect.

7 ge, denervation of ischemic myocardium and a placebo effect.

8 large proportion of patients experiencing a placebo effect.

9 antidepressant who improved as a result of a placebo effect.

10 hat light treatment has a benefit beyond its placebo effect.

11 emodynamic benefit, suggesting the role of a placebo effect.

12 such accounts are potentially biased by the placebo effect.

13 ely a result of other factors, including the placebo effect.

14 an effect on its own; commonly known as the placebo effect.

15 objective measurement, not influenced by the placebo effect.

16 c effects, but no evidence supported a large placebo effect.

17 ratio to measure nausea and thus the gastric placebo effect.

18 efits of microdosing can be explained by the placebo effect.

19 mune system appear to be prerequisites for a placebo effect.

20 oups, but not at 6 months, denoting an early placebo effect.

21 luenced by expectations, as evidenced by the placebo effect.

22 y, when taking into account the experimental placebo effect.

23 t of therapeutic expectations, the so-called placebo effect.

24 drugs, possibly because of the integrated IA placebo effect.

25 We cannot reject the null hypothesis of no placebo effect.

26 gh risk of bias, particularly because of the placebo effect.

27 was associated with a clinically significant placebo effect.

28 s even been ascribed to a "barbaric" form of placebo effect.

29 TX) in descending modulation of pain and the placebo effect.

30 extended into clinically relevant models of placebo effect.

31 ption-anticipation differentials, and actual placebo effects.

32 h regular physical exercise, and nonspecific placebo effects.

33 anticipated to be susceptible to substantial placebo effects.

34 hanisms have been suggested to contribute to placebo effects.

35 am device) may yield different magnitudes of placebo effects.

36 nctional MRI and PET neuroimaging studies of placebo effects.

37 tervention with low risk involves harnessing placebo effects.

38 tion-the self in context-that is crucial for placebo effects.

39 merge as central brain structures underlying placebo effects.

40 nt and enhance understanding of tDCS-related placebo effects.

41 or for a novel and ethical method to harness placebo effects.

42 fluence on the generation and maintenance of placebo effects.

43 t disorders, and the correlates of increased placebo effects.

44 d speech processing, thereby controlling for placebo effects.

45 , which can be difficult to distinguish from placebo effects.

46 design mechanism to reduce the influence of placebo effects.

47 luid intelligence: specifically, the role of placebo effects.

48 logical systems involved in the formation of placebo effects.

49 epsy, and to identify methods of diminishing placebo effects.

50 mechanisms in theory and research regarding placebo effects.

51 and opioid transmitters on the formation of placebo effects.

52 principles and implications of differential placebo effects.

53 urotransmission in regions known involved in placebo effects.

54 n the neurobiological mechanisms involved in placebo effects.

55 otentially having a role in the formation of placebo effects.

56 conditioning, provide signals that activate placebo effects.

57 eptible to both placebo and nocebo (negative placebo) effects.

58 ement was most consistent with a substantial placebo effect; (3) longer, uncontrolled pacing periods

59 he u-opioid system-extensively implicated in placebo effects, a clinical phenomenon thought to rely o

60 Three components bring forth the placebo effect: (a) positive beliefs and expectations on

61 The placebo effect accounted for 88.1%, 55.2%, and 61.3% of

62 Our study indicates differential placebo effect across MDD, BD, and SCZ, which is importa

63 The placebo effect across psychiatric disorders is still not

64 Further examination of the placebo effect across the anxiety disorders may elucidat

65 a common set of brain regions implicated in placebo effects across healthy individuals and patient p

66 ortant for future neurobiological studies of placebo effects across psychiatric disorders and may lea

67 measures and analyses, we found differential placebo effects across the three disorders, and found lo

68 Clinical Global Impression scores to compare placebo effects across these disorders.

69 ficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field tr

70 cognition, frailty, and activity suggesting placebo effect and benefits of trial participation.

71 one by reviewing current knowledge about the placebo effect and how it may pertain to alternative med

72 ns in the measurement of pain, the mind-body placebo effect and the impact of differences in the cond

73 However, the magnitude of the placebo effect and whether it differs across treatment m

74 enuine neuromodulation, (b) via non-specific placebo effects and (c) by demonstrating, through its im

75 ght emerging research on the neurobiology of placebo effects and analyze fundamental questions of mea

76 stent with predictive processing accounts of placebo effects and chronic pain.

77 ian interactions significantly contribute to placebo effects and clinical outcomes.

78 re the use of active placebos to control for placebo effects and dose titration to adjust for interin

79 Finally, we examine ways to enhance placebo effects and reduce the impact of the nocebo resp

80 emonstrates that arginine vasopressin boosts placebo effects and that the effect of vasopressin depen

81 orrelations between the baseline to endpoint placebo effects and the baseline to endpoint drug effect

82 ions of clinical trials, the neurobiology of placebo effects and the implications of placebo effect f

83 However, despite the strength of placebo effects and their impact on everyday human exper

84 al trials are now needed to exclude possible placebo effects and to determine whether fMRI-based neur

85 e factors contributing to a large/increasing placebo effect, and problems with statistical analyses.

86 when we compared pure cue effects with pure placebo effects, and only predictive cues modulated resp

87 The placebo effect appears to be relatively large (up to 77%

88 Placebo effects are beneficial health outcomes not relat

89 Placebo effects are commonly observed in benzodiazepine

90 Placebo effects are especially prominent in Parkinson's

91 Therapeutic patterns that heighten placebo effects are especially prominent in unconvention

92 and in other fields of medicine suggest that placebo effects are likely to be an important aspect of

93 These results show that non-deceptive placebo effects are not merely a product of response bia

94 Placebo effects are notable demonstrations of mind-body

95 It focuses on how placebo effects are shaped by expectations, affect, and

96 underlying the persistence of antidepressant placebo effects are still poorly understood.

97 Meta-analyses of clinical trials reveal that placebo effects are strongest in pain, indicating that p

98 Nonspecific effects, particularly placebo effects, are thought to contribute significantly

99 pectations were significantly related to the placebo effect, as was the belief of receiving active st

100 The observed placebo effect-associated pattern involved metabolic act

101 trials, resulting in nearly double the drug-placebo effect at half the sample size.

102 a specific antidepressant effect beyond its placebo effect, but it took at least 3 weeks for a signi

103 for atrial fibrillation may have a profound placebo effect, but no double-blind randomized clinical

104 are important psychological determinants of placebo effects, but their underlying brain mechanisms a

105 Here, we explore the possibility to boost placebo effects by targeting pharmacologically the vasop

106 This study demonstrates that the placebo effect can be expanded to include individuals' i

107 Placebo effects can be clinically meaningful and can riv

108 There is growing evidence that placebo effects can meaningfully modulate the brain.

109 Differential placebo effects can substantially alter estimates of the

110 t nocebo effects, sometimes termed "negative placebo effects," can contribute appreciably to a variet

111 anism of action, and the contribution of the placebo effect cannot be quantified, this unmasked study

112 treatment for these patients, but presently placebo effects cannot be ruled out.

113 Besides the perspective that placebo effects confound randomized clinical trials, the

114 Placebo effects constitute a major part of treatment suc

115 Placebo effects contribute substantially to the therapeu

116 The differential placebo effects could also distinguish the condition inv

117 o clarify the psychological model underlying placebo effects could merge with the evolving neurobiolo

118 The placebo effect demonstrates how positive expectancies sh

119 analyses to investigate whether the power of placebo effect depends on the types of psychiatric disor

120 cts, perception-anticipation mismatches, and placebo effect development.

121 hanisms other than those associated with the placebo effect (e.g., conditioning, psychosocial context

122 l placebos (OLPs) offer a new way to harness placebo effects ethically.

123 a result of true drug effect (as opposed to placebo effect) exceed chance with pattern analysis.

124 ts when recommending a treatment with only a placebo effect for infants and toddlers with nonspecific

125 y of placebo effects and the implications of placebo effect for several disorders of neurological rel

126 ults) and found significant and heterogenous placebo effects for all efficacy outcomes, with no publi

127 ed this legislation in 2015.220 (43%) of 514 placebo effects for neonatal mortality and 112 (39%) of

128 The magnitude of the placebo effect found in this systematic review and meta-

129 ew technologies reporting unexpectedly large placebo effects from sham devices/procedures needed to m

130 The estimated surgical placebo effect had a standardized mean difference (SMD)

131 the neurobiology of pain perception and the placebo effect has also played a role.

132 r understanding and conceptualization of the placebo effect has shifted in emphasis from a focus on t

133 Research and theory on placebo effects has illuminated much regarding the neuro

134 therapeutics(7), the neural circuit basis of placebo effects has remained unclear.

135 biological model to fulfill the promise that placebo effects have for improving patient outcomes.

136 s provide evidence of a socially transmitted placebo effect, highlighting how healthcare providers' b

137 ically, clinical trials have aimed to reduce placebo effects; however, currently, there is interest i

138 They are also thought to underlie placebo effects, impacting perceptions and biological pr

139 ask Force, in order to better understand the placebo effect in AIT and its specific role in comorbidi

140 ights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b)

141 a substantial antidepressant effect beyond a placebo effect in clinical trials, highlighting the need

142 The placebo effect in depression clinical trials is a substa

143 across the three disorders, and found lower placebo effect in SCZ compared to mood disorders.

144 reatment expectations may be a source of the placebo effect in tDCS research, and identify ways to po

145 ferent than active treatment in men, but the placebo effect in women was negligible and the treatment

146 ed trial whether patient expectancy mediates placebo effects in antidepressant studies.

147 Causes of placebo effects in antidepressant trials have been infer

148 ient expectancy is a significant mediator of placebo effects in antidepressant trials.

149 Exploring placebo effects in chronic interventions is imperative t

150 , underscoring the importance of considering placebo effects in clinical trials.

151 ions were employed to clarify the sources of placebo effects in epilepsy, and to identify methods of

152 uitment in an effort to evaluate the role of placebo effects in fluid intelligence gains from cogniti

153 Clinically relevant placebo effects in nausea have been demonstrated, but it

154 igate the interplay between acute stress and placebo effects in nausea.

155 This study examined placebo effects in pain by using positron-emission tomog

156 ique drama of this realm may have "enhanced" placebo effects in particular conditions.

157 k analysis to study the circuitry underlying placebo effects in PD subjects randomized to sham surger

158 ed to quantify and disentangle treatment and placebo effects in randomized clinical trials comparing

159 in many of these regions was correlated with placebo effects in reported pain.

160 revious studies failed to observe consistent placebo effects in rodent models of chronic pain.

161 Importantly, placebo effects in the lead-in phase were evident and th

162 tment, allowing a comparison of practice and placebo effects in the same patients.

163 Placebo effects in treatment of three anxiety disorders

164 importantly, opens the doors to account for placebo effects in unblinded trials.

165 Vasopressin agonists boosted placebo effects in women but had no effect in men.

166 (upper limit of 95% CI) to account for this "placebo effect" in sample size calculations for future c

167 ly linked to information integration and the placebo effect, including the anterior insula, dorsolate

168 e therapies are accompanied by a substantial placebo effect, indicating that inhibitory circuits in t

169 k of efficacy could be due to a considerable placebo effect; insensitivity of scales to quantify stif

170 tempt to incorporate factors associated with placebo effects into clinical care.

171 The placebo effect is partly the result of positive expectat

172 The term placebo effect is taken to mean not only the narrow effe

173 s a consequence, the formation of biological placebo effects is now being linked to the concept of re

174 'Differential placebo effects' is the concept that different types of

175 Currently, the placebo effect literature concentrates more on neurobiol

176 es for comparative spatial analysis with the placebo effects maps.

177 eizure reduction traditionally attributed to placebo effect may reflect the natural course of the dis

178 molecular changes, results suggest that the placebo effects may induce molecular responses within th

179 we found no difference between treatment and placebo effects (MD = -0.29, 95% CI -0.62 to 0.05, P = 0

180 cognitive and behavioral exercises targeting placebo effect mechanisms improves benzodiazepine recept

181 These findings likely encompass the true placebo effect, natural disease course, and nonspecific

182 A potentially strong placebo effect needs to be ruled out in future studies.

183 benefits of chronic RET were independent of placebo effects, notwithstanding the potential limitatio

184 Furthermore, the expected placebo effect observed in studies of functional capacit

185 the objective measures may be explicable as placebo effects/observer bias.

186 This essay looks at the placebo effect of alternative medicine as a distinct ent

187 ifficult by the fluctuating symptoms and the placebo effect of invasive interventions.

188 raining than the control group, suggesting a placebo effect of tDCS.

189 lled trials cannot be overemphasized, as the placebo effect of these therapies is probably marked.

190 significance of its own placebo effect, the placebo effect of unconventional medicine is disregarded

191 -related fatigue, as well as the substantial placebo effects of psychostimulants, and may benefit fro

192 ly prospective trials directly comparing the placebo effects of unconventional and mainstream medicin

193 determine whether tDCS can have a measurable placebo effect on cognitive training and to identify pot

194 There was no placebo effect on FMV or SUA.

195 Greater drug-versus-placebo effects on caudate activation significantly corr

196 Also addressed are the identification of placebo effects on drugs, the relevance of active placeb

197 We assessed placebo effects on efficacy and nocebo effects on tolera

198 into the neural time course of non-deceptive placebo effects on emotional distress and the psychologi

199 We examined deceptive and open-label placebo effects on guilt, which is important for self-re

200 We examine the brain systems underlying placebo effects on pain, autonomic, and immune responses

201 studies attempting to understand the role of placebo effects on patients receiving a drug.

202 Results suggest that placebo effects on symptoms of nausea and motion sicknes

203 ment might be the result of, for instance, a placebo effect or postoperative physiotherapy.

204 Five components of the placebo effect--patient, practitioner, patient-practitio

205 Nonetheless, the possibility of enhanced placebo effects raises complex conundrums.

206 Placebo effects refer specifically to short-lasting impr

207 The dominant theories of human placebo effects rely on a notion that consciously percep

208 This placebo effect shows that the benefits of tDCS on cognit

209 of antidepressant medication represents the placebo effect, since many depressed patients improve wh

210 alopram was not significantly different from placebo (effect size, 0.03 HAM-D points; 95% CI, -0.7 to

211 redible interval, 0.09 to 0.49]) and topical placebo (effect size, 0.20 [credible interval, 0.02 to 0

212 ferential model) showed that intra-articular placebo (effect size, 0.29 [95% credible interval, 0.09

213 as associated with the probability a smaller placebo effect size (B = -0.12; 95% CI, -0.23 to -0.01,

214 We explored whether placebo effect size differs across distinct disorders, a

215 The pooled placebo effect size for all modalities was large (g = 1.

216 was large (g = 1.05; 95% CI, 0.91-1.1); the placebo effect size in RCTs of specific treatment modali

217 Placebo effect size varied, and was large in alcohol use

218 Placebo effect size was small-to-medium in obsessive-com

219 patients with TRD standardizing an expected placebo effect size.

220 hree variables were associated with a larger placebo effect size: open-label prospective treatment be

221 re of 20-25 (9.26 for olanzapine vs 6.70 for placebo; effect size 0.35, 95% CI 0.11-0.60), by 4.74 po

222 The primary outcome, pooled pre-post placebo effect sizes (dav) with 95% CIs per diagnosis, w

223 Pooled pre-post placebo effect sizes differed across diagnoses (Q = 88.5

224 munological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological li

225 matic reviews and/or meta-analyses reporting placebo effect sizes in psychopharmacological or neurost

226 Placebo effect sizes varied substantially across mental

227 he largest vasopressin-induced modulation of placebo effects, suggesting a moderating interplay betwe

228 The placebo effect suppresses the probability that an indivi

229 al interactions strongly contribute to evoke placebo effects that are pervasive in medicine and depen

230 Placebo effects that were evaluated by using a network m

231 ignores the clinical significance of its own placebo effect, the placebo effect of unconventional med

232 While our design was unable to rule out placebo effects, the magnitude and durability of improve

233 tion, pain-touch and pain-pain interactions, placebo effects, the role of attention and emotion in pa

234 ily negative connotations of the very words "placebo effect, " the term should be replaced by "rememb

235 bo treatment alone, a phenomenon termed "the placebo effect." This phenomenon confounds the results a

236 of the legislation effects with that of the placebo effects to assess the likelihood that the observ

237 , currently, there is interest in optimizing placebo effects to improve existing treatments and in ex

238 responses to pharmacologic and psychological/placebo effects underlying binge drinking are lacking.

239 etic variation were examined controlling for placebo effects using general linear and mixed effects m

240 signed a procedure to intentionally induce a placebo effect via overt recruitment in an effort to eva

241 f agave nectar, placebo, and no treatment, a placebo effect was demonstrated, with no additional bene

242 The placebo effect was greatest for clinician compared with

243 Hydration was well tolerated, and a placebo effect was observed.

244 The evidence that the placebo effect was responsible for progressive intraocul

245 The placebo effect was very strong in this study, demonstrat

246 To estimate the magnitude of the placebo effect, we pooled the difference in outcome betw

247 at for a half century has been known as the "placebo effect." We argue that, as currently used, the c

248 Treatment vs. placebo effects were examined in multi-level mixed-effec

249 icles identified, 34 neuroimaging studies of placebo effects were included.

250 at on a timescale of minutes, antidepressant placebo effects were maintained by positive feedback loo

251 Placebo effects were minimal and associated with the num

252 Treatment and placebo effects were not different in 22 out of 28 prede

253 Importantly, no significant adverse or placebo effects were seen.

254 omised clinical trials (RCTs) to control for placebo effects, which can be large.

255 , the benefits of tDCS may be due in part to placebo effects, which have not been well-characterized.

256 an alleviate distress and reduce pain (e.g., placebo effect), while negative expectations may heighte

257 ake on the difficult task of controlling for placebo effects will allow patients' subjective ratings

258 Understanding these placebo effects will help to improve clinical trial desi

259 yncope, raise the potential of a significant placebo effect with pharmacologic therapy.

260 ory and clinical studies in the field of the placebo effect, with a particular focus on psychiatric d

261 nization device therapy exerts a substantial placebo effect, with evidence of improved functional cap

262 o test for differences between treatment and placebo effects within similar trial populations.

263 They have the potential to harness placebo effects without deceiving the patient.

264 step further, this study aimed at evaluating placebo effects without the use of a physical placebo, i

265 The placebo effect yields beneficial clinical results in 60-